These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 20019813)

  • 21. CD8 T cell recognition of endogenously expressed epstein-barr virus nuclear antigen 1.
    Lee SP; Brooks JM; Al-Jarrah H; Thomas WA; Haigh TA; Taylor GS; Humme S; Schepers A; Hammerschmidt W; Yates JL; Rickinson AB; Blake NW
    J Exp Med; 2004 May; 199(10):1409-20. PubMed ID: 15148339
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mature proteins derived from Epstein-Barr virus fail to feed into the MHC class I antigenic pool.
    Fiebiger BM; Moosmann A; Behrends U; Mautner J
    Eur J Immunol; 2012 Dec; 42(12):3167-73. PubMed ID: 22944914
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epstein-Barr virus strain heterogeneity impairs human T-cell immunity.
    Cirac A; Stützle S; Dieckmeyer M; Adhikary D; Moosmann A; Körber N; Bauer T; Witter K; Delecluse HJ; Behrends U; Mautner J
    Cancer Immunol Immunother; 2018 Apr; 67(4):663-674. PubMed ID: 29374782
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early T Cell Recognition of B Cells following Epstein-Barr Virus Infection: Identifying Potential Targets for Prophylactic Vaccination.
    Brooks JM; Long HM; Tierney RJ; Shannon-Lowe C; Leese AM; Fitzpatrick M; Taylor GS; Rickinson AB
    PLoS Pathog; 2016 Apr; 12(4):e1005549. PubMed ID: 27096949
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term MHC class II presentation of the EBV lytic protein BHRF1 by EBV latently infected b cells following capture of BHRF1 antigen.
    Landais E; Saulquin X; Bonneville M; Houssaint E
    J Immunol; 2005 Dec; 175(12):7939-46. PubMed ID: 16339529
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regression of Epstein-Barr virus-induced B-cell transformation in vitro involves virus-specific CD8+ T cells as the principal effectors and a novel CD4+ T-cell reactivity.
    Gudgeon NH; Taylor GS; Long HM; Haigh TA; Rickinson AB
    J Virol; 2005 May; 79(9):5477-88. PubMed ID: 15827162
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Melanoma-specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells.
    Topalian SL; Rivoltini L; Mancini M; Ng J; Hartzman RJ; Rosenberg SA
    Int J Cancer; 1994 Jul; 58(1):69-79. PubMed ID: 7516926
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Virus-specific cytotoxic CD4+ T cells for the treatment of EBV-related tumors.
    Merlo A; Turrini R; Bobisse S; Zamarchi R; Alaggio R; Dolcetti R; Mautner J; Zanovello P; Amadori A; Rosato A
    J Immunol; 2010 May; 184(10):5895-902. PubMed ID: 20385879
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nuclear location of an endogenously expressed antigen, EBNA1, restricts access to macroautophagy and the range of CD4 epitope display.
    Leung CS; Haigh TA; Mackay LK; Rickinson AB; Taylor GS
    Proc Natl Acad Sci U S A; 2010 Feb; 107(5):2165-70. PubMed ID: 20133861
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of novel Epstein-Barr virus-derived antigen formulations for monitoring virus-specific T cells in pediatric patients with infectious mononucleosis.
    Fischer F; Mücke J; Werny L; Gerrer K; Mihatsch L; Zehetmaier S; Riedel I; Geisperger J; Bodenhausen M; Schulte-Hillen L; Hoffmann D; Protzer U; Mautner J; Behrends U; Bauer T; Körber N
    Virol J; 2024 Jun; 21(1):139. PubMed ID: 38877590
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The EBV immunoevasins vIL-10 and BNLF2a protect newly infected B cells from immune recognition and elimination.
    Jochum S; Moosmann A; Lang S; Hammerschmidt W; Zeidler R
    PLoS Pathog; 2012; 8(5):e1002704. PubMed ID: 22615564
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential evolution and stability of epitope-specific CD8(+) T cell responses in EBV infection.
    Catalina MD; Sullivan JL; Bak KR; Luzuriaga K
    J Immunol; 2001 Oct; 167(8):4450-7. PubMed ID: 11591771
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cooperation between Epstein-Barr virus immune evasion proteins spreads protection from CD8+ T cell recognition across all three phases of the lytic cycle.
    Quinn LL; Zuo J; Abbott RJ; Shannon-Lowe C; Tierney RJ; Hislop AD; Rowe M
    PLoS Pathog; 2014 Aug; 10(8):e1004322. PubMed ID: 25144360
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers.
    Tan LC; Gudgeon N; Annels NE; Hansasuta P; O'Callaghan CA; Rowland-Jones S; McMichael AJ; Rickinson AB; Callan MF
    J Immunol; 1999 Feb; 162(3):1827-35. PubMed ID: 9973448
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Absence of Epstein-Barr virus-specific, HLA class II-restricted CD4+ cytotoxic T lymphocytes in infectious mononucleosis.
    Enssle KH; Fleischer B
    Clin Exp Immunol; 1990 Mar; 79(3):409-15. PubMed ID: 1690617
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting the nuclear antigen 1 of Epstein-Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses.
    Gurer C; Strowig T; Brilot F; Pack M; Trumpfheller C; Arrey F; Park CG; Steinman RM; Münz C
    Blood; 2008 Aug; 112(4):1231-9. PubMed ID: 18519810
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Isolation of cytotoxic T lymphocytes from healthy seropositive individuals specific for peptide epitopes from Epstein-Barr virus nuclear antigen 1: implications for viral persistence and tumor surveillance.
    Khanna R; Burrows SR; Steigerwald-Mullen PM; Thomson SA; Kurilla MG; Moss DJ
    Virology; 1995 Dec; 214(2):633-7. PubMed ID: 8553567
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Missing Link in Epstein-Barr Virus Immune Evasion: the BDLF3 Gene Induces Ubiquitination and Downregulation of Major Histocompatibility Complex Class I (MHC-I) and MHC-II.
    Quinn LL; Williams LR; White C; Forrest C; Zuo J; Rowe M
    J Virol; 2016 Jan; 90(1):356-67. PubMed ID: 26468525
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acquisition of polyfunctionality by Epstein-Barr virus-specific CD8+ T cells correlates with increased resistance to galectin-1-mediated suppression.
    Smith C; Beagley L; Khanna R
    J Virol; 2009 Jun; 83(12):6192-8. PubMed ID: 19357166
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The human T cell immune response to Epstein-Barr virus.
    Landais E; Saulquin X; Houssaint E
    Int J Dev Biol; 2005; 49(2-3):285-92. PubMed ID: 15906243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.